Current strategies in the treatment of Parkinson's disease and a personalized approach to management.
Parkinson's disease is a progressive, neurodegenerative disorder affecting millions of people worldwide. Given the aging population, the prevalence of the disease is expected to increase substantially. The mainstay of treatment has been dopamine replacement therapy with carbidopa, levodopa, dopamine agonists, monoamine oxidase type B inhibitors, catechol-O-methyltransferase inhibitors and amantadine. Nonmotor features, such as cognitive impairment, mood disorders, autonomic dysfunction, gastrointestinal and genitourinary dysfunction, have a substantial impact on Parkinson's disease patients and their quality of life. This review will provide an overview on medications currently available for management of both motor and nonmotor symptoms of Parkinson's disease. Focus will be placed on recent and evolving studies evaluating symptomatic and neuroprotective effects of medications, and how such studies may impact the future management of Parkinson's disease.
Diaz
Nancy L
NL
Neurological Institute at Columbia University Medical Center, 710 W168th St, 3rd floor, New York, NY 10032, USA. nd2284@mail.cumc.columbia.edu
Waters
Cheryl H
CH
D000978:Antiparkinson Agents / Q000009:adverse effects / Q000145:classification / Q000627:therapeutic use; D001342:Autonomic Nervous System Diseases / Q000209:etiology / Q000628:therapy; D018680:Cholinergic Antagonists / Q000627:therapeutic use; D017322:Clinical Trials, Phase II as Topic; D046690:Deep Brain Stimulation; D003863:Depression / Q000209:etiology / Q000628:therapy; D018491:Dopamine Agonists / Q000627:therapeutic use; D006801:Humans; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D015337:Multicenter Studies as Topic; D010300:Parkinson Disease / Q000150:complications* / Q000188:drug therapy / Q000628:therapy*; D011618:Psychotic Disorders / Q000209:etiology / Q000628:therapy
D000978:Antiparkinson Agents; D018680:Cholinergic Antagonists; D018491:Dopamine Agonists; D008996:Monoamine Oxidase Inhibitors